- Home
- NEWT vs AVIR Comparison
NEWT vs AVIR Comparison
Compare NEWT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- AVIR
- Stock Information
- Founded
- NEWT 1998
- AVIR 2012
- Country
- NEWT United States
- AVIR United States
- Employees
- NEWT 591
- AVIR N/A
- Industry
- NEWT Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- NEWT Finance
- AVIR Health Care
- Exchange
- NEWT Nasdaq
- AVIR Nasdaq
- Market Cap
- NEWT 316.7M
- AVIR 290.4M
- IPO Year
- NEWT N/A
- AVIR 2020
- Fundamental
- Price
- NEWT $12.03
- AVIR $2.91
- Analyst Decision
- NEWT Hold
- AVIR Hold
- Analyst Count
- NEWT 4
- AVIR 1
- Target Price
- NEWT $13.00
- AVIR $6.00
- AVG Volume (30 Days)
- NEWT 163.1K
- AVIR 217.7K
- Earning Date
- NEWT 11-05-2025
- AVIR 11-06-2025
- Dividend Yield
- NEWT 6.41%
- AVIR N/A
- EPS Growth
- NEWT 21.23
- AVIR N/A
- EPS
- NEWT 2.01
- AVIR N/A
- Revenue
- NEWT $364,004,000.00
- AVIR N/A
- Revenue This Year
- NEWT N/A
- AVIR N/A
- Revenue Next Year
- NEWT $12.73
- AVIR N/A
- P/E Ratio
- NEWT $5.89
- AVIR N/A
- Revenue Growth
- NEWT 20.91
- AVIR N/A
- 52 Week Low
- NEWT $9.12
- AVIR $2.46
- 52 Week High
- NEWT $15.49
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- NEWT 52.65
- AVIR 29.44
- Support Level
- NEWT $11.44
- AVIR $3.10
- Resistance Level
- NEWT $11.77
- AVIR $3.33
- Average True Range (ATR)
- NEWT 0.30
- AVIR 0.14
- MACD
- NEWT -0.04
- AVIR -0.05
- Stochastic Oscillator
- NEWT 57.28
- AVIR 7.69
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).